WO2010097694A1 - A heart valve - Google Patents

A heart valve Download PDF

Info

Publication number
WO2010097694A1
WO2010097694A1 PCT/IB2010/000398 IB2010000398W WO2010097694A1 WO 2010097694 A1 WO2010097694 A1 WO 2010097694A1 IB 2010000398 W IB2010000398 W IB 2010000398W WO 2010097694 A1 WO2010097694 A1 WO 2010097694A1
Authority
WO
WIPO (PCT)
Prior art keywords
stent
heart valve
valve
sleeve
struts
Prior art date
Application number
PCT/IB2010/000398
Other languages
French (fr)
Inventor
Anton Frans Doubell
Cornelius Scheffer
Hellmuth Stephan Von Heyderhoff Weich
Albert Anne Groenwold
Anton Heinrich Esterhuyse
Adriaan Nicolaas Smuts
Kari Van Aswegen
Deborah Clare Blaine
Kobus Van Der Westhuizen
Original Assignee
Stellenbosch University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Stellenbosch University filed Critical Stellenbosch University
Priority to CN2010800097454A priority Critical patent/CN102395330A/en
Priority to AU2010217291A priority patent/AU2010217291B2/en
Publication of WO2010097694A1 publication Critical patent/WO2010097694A1/en
Priority to ZA2011/06839A priority patent/ZA201106839B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2418Scaffolds therefor, e.g. support stents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0482Needle or suture guides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61BDIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00Surgical instruments, devices or methods, e.g. tourniquets
    • A61B17/04Surgical instruments, devices or methods, e.g. tourniquets for suturing wounds; Holders or packages for needles or suture materials
    • A61B17/0483Hand-held instruments for holding sutures
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/02Prostheses implantable into the body
    • A61F2/24Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body
    • A61F2/2412Heart valves ; Vascular valves, e.g. venous valves; Heart implants, e.g. passive devices for improving the function of the native valve or the heart muscle; Transmyocardial revascularisation [TMR] devices; Valves implantable in the body with soft flexible valve members, e.g. tissue valves shaped like natural valves
    • A61F2/2415Manufacturing methods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2220/00Fixations or connections for prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2220/0025Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements
    • A61F2220/0075Connections or couplings between prosthetic parts, e.g. between modular parts; Connecting elements sutured, ligatured or stitched, retained or tied with a rope, string, thread, wire or cable
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61FFILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2230/00Geometry of prostheses classified in groups A61F2/00 - A61F2/26 or A61F2/82 or A61F9/00 or A61F11/00 or subgroups thereof
    • A61F2230/0002Two-dimensional shapes, e.g. cross-sections
    • A61F2230/0028Shapes in the form of latin or greek characters
    • A61F2230/0054V-shaped

Definitions

  • This invention relates to an artificial heart replacement valve.
  • Heart valves It is known to replace heart valves with artificial valves.
  • One form of heart valve includes a valve located within a collapsible mesh tube or stent.
  • the stent is supplied in a collapsed condition and typically inserted into the body through a vein or artery. Once in position it is expanded using an inflatable balloon.
  • the valve is secured in position by the friction between the native tissue and the stent. After a few weeks the valve becomes more firmly secured through tissue in-growth. Prior to tissue in-growth initial valve migration is however a concern with these type of valves.
  • Heart valves are generally secured within the heart valve annulus within the native valve. In so doing they maintain the native valve open and obviate the need to remove it.
  • One of the problems typically experienced with such heart valves is that there is limited space for the introduction of the valve in a collapsed or crimped state prior to being expanded by the balloon.
  • valve member usually is made up of three flexible leaflets (or cusps as they are sometimes referred to for certain applications but herein referred to as leaflets irrespective of the application) joined along their sides to form a triangular shape.
  • leaflets or cusps as they are sometimes referred to for certain applications but herein referred to as leaflets irrespective of the application.
  • the construction of these leaflets is not always optimal and the materials used to date do not exhibit characteristics required for extended use, such as wear resistance and resistance to calcification.
  • a heart valve which includes a valve member secured within a stent with the valve member including a plurality of valve leaflets secured together, the heart valve being characterised in that the leaflets are made of biological material having a maximum thickness of 0.3 mm.
  • the biological material to have a maximum thickness of 0.25 mm; for each leaflet to have an arcuate, preferably generally parabolically shaped side for attachment to the stent; for the stent, in its crimped condition, to have a maximum diameter of 7.5 mm and preferably about 7 mm; for the biological material to be suitably treated kangaroo tissue; and for the kangaroo tissue to be a tissue treated using the ADAPTTM technology of Celxcel Pty Limited (BbMD Limited) of Perth,
  • the invention also provides for a sleeve made of a porous, biocompatible material to extend about the outer surface of the stent at least partially along its length.
  • the material of the sleeve is preferably selected from porous polyester and expanded polytetraflouroethylene (PTFE) 1 preferably ultrathin porous polyester.
  • PTFE polytetraflouroethylene
  • the sleeve may extend the length of the stent and the sleeve typically has a thickness of 0.1 mm to 0.5mm, preferably 0.2mm.
  • the sleeve may be secured to the stent by stitching typically extending along each end thereof.
  • the invention also provides a heart valve which includes a valve member secured within an expandable stent having two ends and a central region with the valve member including a plurality of valve leaflets secured together, the heart valve being characterised in that the stent is configured to initially expand at both ends.
  • the stent to be in the form of a mesh defined by interconnected struts; for the material of the stent to be strengthened in the central region thereof especially by making the struts in that region stronger than the struts in the end regions, typically by making the struts somewhat larger in cross-section; and for the stent to be made of cobalt-chrome (MP25N).
  • MP25N cobalt-chrome
  • the invention further provides a tool for use in stitching a valve member to a stent comprising a pair of elongate jaws each having a slot extending partway along its length.
  • Figure 1 is a perspective view of a heart valve
  • Figure 2 is a side elevation of the heart valve in Figure 1 ;
  • Figure 3 is a perspective view of a stent used in the heart valve of Figure 1 ;
  • Figure 4 is a perspective view of a valve member used in the heart valve illustrated in Figure 1 ;
  • Figure 5 is a side elevation of a valve leaflet for the valve member illustrated in Figure 4.
  • Figure 6 is a side elevation of a second embodiment of a stent for a heart valve.
  • a heart valve (1 ) is shown in Figures 1 and 2 and includes a tubular stent (2) having a valve member (4) secured internally thereof and an external sleeve (6).
  • the stent (2) is cylindrical and is formed by laser cutting a plurality of concentric diamond-shaped holes in a length of cobalt-chrome (MP35N) tubing.
  • MP35N cobalt-chrome
  • the stent (2) is shown in its expanded condition in which it has a length of between 20 and 22mm and a diameter of between 23 and 26mm. However, in the manufacture of the stent (2) a cobalt-chrome tube of 10mm diameter is used. The tube is expanded after cutting and the valve member (4) and sleeve (6) secured thereto. The assembled heart valve (1 ) is then crimped over a balloon catheter (not shown) in conventional manner.
  • the valve member is formed from three valve leaflets, each cut from a sheet of kangaroo tissue which has been treated using the ADAPTTM technology of Celxcel Pty Limited.
  • Each leaflet (12) has a straight outlet side (14) with normally extending sides (16) at each end, each approximately a third of the length of the outlet side (14).
  • An arcuate inlet side (18) extends between the sides (16) opposite the outlet side (14).
  • the inlet side (18) has a parabolic shape.
  • the leaflets (12) are secured together along their sides (16) to form a triangular shape by a row of stitching (20) which tapers slightly inwardly from the start of the abutting inlet sides (18) towards the outlet sides (14).
  • valve member (4) is subsequently secured within the stent (2) by stitching along the sides (16, 18) as indicated in Figure 5 by the dots (22). It will be appreciated that the parabolic shape of the inlet side (18) of each leaflet (12) corresponds to the shape of an inclined section through the stent (2) along which each leaflet (12) is secured thereto.
  • the use of the treated kangaroo tissue has a number of advantages. Firstly, the tissue is flexible and resistant to wear. Secondly, it resists calcification and thus retains its flexibility for extended periods. Thirdly, it is relatively tough and can consequently be thinner than many other materials used in this application. In this embodiment, the leaflets each have a maximum thickness of 0.22mm. This characteristic of treated kangaroo tissue is especially important as it enables the entire heart valve in its crimped state in which it is ready for introduction into the human body to be appreciably smaller in diameter than in the instance of other heart valves presently used.
  • kangaroo tissue enables the crimped heart valve to have a diameter of 6.7 mm [20 French] whereas the conventional prior art crimped heart valve has a diameter of 8.0 mm [24 French]. This is a significant reduction in size and it is envisaged that it will greatly facilitate initial placement of the crimped heart valve.
  • the sleeve (6) is provided about the outer surface of the stent (2).
  • the sleeve is made of a porous, biocompatible material, in this embodiment ultra-thin porous polyester having a thickness of 0.2 mm.
  • the ends of the sleeve (6) conform to those (8, 9) of the stent (2) and stitching (24, 26) along each of the ends (8, 9)- secures the sleeve (6) to the stent (2).
  • the sleeve (6) is further secured in position by the stitching securing the valve member (4) to the stent, the stitching extending about both the stent and the corresponding portion of the sleeve (6).
  • the sleeve (6) has two major functions. The first is to provide a porous surface for tissue in-growth which assists in securing the heart valve (1 ) in position after implantation. The second function is to provide increased resistance between the heart valve and the arterial wall and to so prevent migration of the device after implantation. Critically, the sleeve also assists in preventing blood leakage between the heart valve (1 ) and arterial wall. This greatly increases the effectiveness of the heart valve.
  • any suitable material can be used for the sleeve including expanded PTFE.
  • Corex sutures are used for all the stitching, but any other suitable material can be used.
  • the valve member can have any suitable shape.
  • the stent too can be made of any suitable material and can have any suitable shape.
  • the stent could be made so that the material at the ends (8, 9) is thinner than that at the centre (30). This will result in the end regions expanding initially during inflation to give the stent a waisted shape as illustrated by the broken lines. This shape will ensure that the heart valve becomes easily centralised within the valve annulus where it can be secured in position before inflating the balloon further to give the stent a more uniform cylindrical shape. This can easily be achieved by making the central bands of struts defining the mesh structure approximately 10% thicker than those at the ends.
  • the tool (40) includes a pair of narrow elongated jaws (42) each extending from a handle (44), the handles being secured together at one end (46).
  • the jaws (42) and handles (44) are made of a stainless steel and are shaped to be biased apart at the end (46).
  • Corresponding slots (48) extend centrally along each jaw (42) from the free end (50) thereof, with the slots (48) each having a series of spaced apart arcuate notches (52) therein.
  • the notches (52) are shaped to receive a sewing needle.
  • the joined sides (16) of leaflets (12) are held against the side of the stent by between the jaws (42) whereafter they are stitched in position, the notches (52) acting as a template to ensure uniformity.
  • the tool is fairly simple to make but greatly facilitates manufacture of the stent as it permits both the valve member to be held in position and to be secured by a stitching whilst being so held. It will be appreciated that other embodiments of a tool exist which fall within the scope of the invention especially as regards the shape of the jaws and the slot therein.

Abstract

A heart valve (1 ) is provided in which a valve member including a plurality of valve leaflets (12) secured together is secured within a stent (2). The leaflets are made of a biologic material that has a maximum thickness of 0.3 mm. Suitably treated kangaroo tissue such as that treated using the ADAPT™ technology is considered appropriate. Each leaflet preferably has an arcuate shaped side (18) for attachment to the stent. The resultant crimped stent may have a maximum diameter of about 7.5 or even 7.0 mm. Preferably, a sleeve (6) made of a porous, biocompatible material extends about the outer surface of the stent, along at least a part, and typically all of its length. Preferably, the stent is configured to initially expand at both ends (8, 9), this being conveniently achieved by using a stent in the form of a mesh defined by interconnected struts with the struts in a central region being stronger than the struts in the end regions.

Description

A HEART VALVE
FIELD OF THE INVENTION
This invention relates to an artificial heart replacement valve.
BACKGROUND TO THE INVENTION
It is known to replace heart valves with artificial valves. One form of heart valve includes a valve located within a collapsible mesh tube or stent. The stent is supplied in a collapsed condition and typically inserted into the body through a vein or artery. Once in position it is expanded using an inflatable balloon. The valve is secured in position by the friction between the native tissue and the stent. After a few weeks the valve becomes more firmly secured through tissue in-growth. Prior to tissue in-growth initial valve migration is however a concern with these type of valves. Heart valves are generally secured within the heart valve annulus within the native valve. In so doing they maintain the native valve open and obviate the need to remove it.
One of the problems typically experienced with such heart valves is that there is limited space for the introduction of the valve in a collapsed or crimped state prior to being expanded by the balloon.
Furthermore, the valve member usually is made up of three flexible leaflets (or cusps as they are sometimes referred to for certain applications but herein referred to as leaflets irrespective of the application) joined along their sides to form a triangular shape. The construction of these leaflets is not always optimal and the materials used to date do not exhibit characteristics required for extended use, such as wear resistance and resistance to calcification.
It can also be difficult to accurately position such valves as there is no direct visualisation of the site and this has to be done indirectly, often using fluoroscopic imaging.
Still further, there can be leakage of blood between the stent and heart valve annulus or between the stent and artery or vein surface.
OBJECT OF THE INVENTION
It is an object of this invention to create a heart valve which will at least partially alleviate one or more of the abovementioned problems.
SUMMARY OF THE INVENTION
In accordance with this invention there is provided a heart valve which includes a valve member secured within a stent with the valve member including a plurality of valve leaflets secured together, the heart valve being characterised in that the leaflets are made of biological material having a maximum thickness of 0.3 mm.
Further features of the invention provide for the biological material to have a maximum thickness of 0.25 mm; for each leaflet to have an arcuate, preferably generally parabolically shaped side for attachment to the stent; for the stent, in its crimped condition, to have a maximum diameter of 7.5 mm and preferably about 7 mm; for the biological material to be suitably treated kangaroo tissue; and for the kangaroo tissue to be a tissue treated using the ADAPT™ technology of Celxcel Pty Limited (BbMD Limited) of Perth,
Western Australia. The invention also provides for a sleeve made of a porous, biocompatible material to extend about the outer surface of the stent at least partially along its length. The material of the sleeve is preferably selected from porous polyester and expanded polytetraflouroethylene (PTFE)1 preferably ultrathin porous polyester. The sleeve may extend the length of the stent and the sleeve typically has a thickness of 0.1 mm to 0.5mm, preferably 0.2mm. The sleeve may be secured to the stent by stitching typically extending along each end thereof.
The invention also provides a heart valve which includes a valve member secured within an expandable stent having two ends and a central region with the valve member including a plurality of valve leaflets secured together, the heart valve being characterised in that the stent is configured to initially expand at both ends.
Further features of this aspect of the invention provide for the stent to be in the form of a mesh defined by interconnected struts; for the material of the stent to be strengthened in the central region thereof especially by making the struts in that region stronger than the struts in the end regions, typically by making the struts somewhat larger in cross-section; and for the stent to be made of cobalt-chrome (MP25N).
The invention further provides a tool for use in stitching a valve member to a stent comprising a pair of elongate jaws each having a slot extending partway along its length.
Further features of the invention provide for at least one side of each slot to have a series of spaced arcuate notches therein.
In order that the above and other features of the invention may be more fully understood one embodiment thereof will now be described with reference to the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS
In the drawings:-
Figure 1 is a perspective view of a heart valve;
Figure 2 is a side elevation of the heart valve in Figure 1 ;
Figure 3 is a perspective view of a stent used in the heart valve of Figure 1 ;
Figure 4 is a perspective view of a valve member used in the heart valve illustrated in Figure 1 ;
Figure 5 is a side elevation of a valve leaflet for the valve member illustrated in Figure 4; and
Figure 6 is a side elevation of a second embodiment of a stent for a heart valve.
DETAILED DESCRIPTION WITH REFERENCE TO THE DRAWINGS
A heart valve (1 ) is shown in Figures 1 and 2 and includes a tubular stent (2) having a valve member (4) secured internally thereof and an external sleeve (6). Referring also to Figure 3, the stent (2) is cylindrical and is formed by laser cutting a plurality of concentric diamond-shaped holes in a length of cobalt-chrome (MP35N) tubing. The stent (2) thus has a diamond mesh appearance with each of its ends (8, 9) being serrated.
The stent (2) is shown in its expanded condition in which it has a length of between 20 and 22mm and a diameter of between 23 and 26mm. However, in the manufacture of the stent (2) a cobalt-chrome tube of 10mm diameter is used. The tube is expanded after cutting and the valve member (4) and sleeve (6) secured thereto. The assembled heart valve (1 ) is then crimped over a balloon catheter (not shown) in conventional manner.
Referring especially to Figures 4 and 5, the valve member is formed from three valve leaflets, each cut from a sheet of kangaroo tissue which has been treated using the ADAPT™ technology of Celxcel Pty Limited. Each leaflet (12) has a straight outlet side (14) with normally extending sides (16) at each end, each approximately a third of the length of the outlet side (14). An arcuate inlet side (18) extends between the sides (16) opposite the outlet side (14). In this embodiment, the inlet side (18) has a parabolic shape.
The leaflets (12) are secured together along their sides (16) to form a triangular shape by a row of stitching (20) which tapers slightly inwardly from the start of the abutting inlet sides (18) towards the outlet sides (14).
The valve member (4) is subsequently secured within the stent (2) by stitching along the sides (16, 18) as indicated in Figure 5 by the dots (22). It will be appreciated that the parabolic shape of the inlet side (18) of each leaflet (12) corresponds to the shape of an inclined section through the stent (2) along which each leaflet (12) is secured thereto.
The use of the treated kangaroo tissue has a number of advantages. Firstly, the tissue is flexible and resistant to wear. Secondly, it resists calcification and thus retains its flexibility for extended periods. Thirdly, it is relatively tough and can consequently be thinner than many other materials used in this application. In this embodiment, the leaflets each have a maximum thickness of 0.22mm. This characteristic of treated kangaroo tissue is especially important as it enables the entire heart valve in its crimped state in which it is ready for introduction into the human body to be appreciably smaller in diameter than in the instance of other heart valves presently used. The use of the kangaroo tissue enables the crimped heart valve to have a diameter of 6.7 mm [20 French] whereas the conventional prior art crimped heart valve has a diameter of 8.0 mm [24 French]. This is a significant reduction in size and it is envisaged that it will greatly facilitate initial placement of the crimped heart valve.
Another important feature of the heart valve (1 ) is the sleeve (6) provided about the outer surface of the stent (2). The sleeve is made of a porous, biocompatible material, in this embodiment ultra-thin porous polyester having a thickness of 0.2 mm. The ends of the sleeve (6) conform to those (8, 9) of the stent (2) and stitching (24, 26) along each of the ends (8, 9)- secures the sleeve (6) to the stent (2). The sleeve (6) is further secured in position by the stitching securing the valve member (4) to the stent, the stitching extending about both the stent and the corresponding portion of the sleeve (6).
The sleeve (6) has two major functions. The first is to provide a porous surface for tissue in-growth which assists in securing the heart valve (1 ) in position after implantation. The second function is to provide increased resistance between the heart valve and the arterial wall and to so prevent migration of the device after implantation. Critically, the sleeve also assists in preventing blood leakage between the heart valve (1 ) and arterial wall. This greatly increases the effectiveness of the heart valve.
It will be appreciated, however, that many other embodiments of a heart valve exist which fall within the scope of the invention. For example, any suitable material can be used for the sleeve including expanded PTFE. In this embodiment, Corex sutures are used for all the stitching, but any other suitable material can be used. Also, the valve member can have any suitable shape. The stent too can be made of any suitable material and can have any suitable shape.
Referring to Figure 6, the stent could be made so that the material at the ends (8, 9) is thinner than that at the centre (30). This will result in the end regions expanding initially during inflation to give the stent a waisted shape as illustrated by the broken lines. This shape will ensure that the heart valve becomes easily centralised within the valve annulus where it can be secured in position before inflating the balloon further to give the stent a more uniform cylindrical shape. This can easily be achieved by making the central bands of struts defining the mesh structure approximately 10% thicker than those at the ends.
As shown in Figure 7, a tool is also provided which assists in suturing the valve member in position on the stent. The tool (40) includes a pair of narrow elongated jaws (42) each extending from a handle (44), the handles being secured together at one end (46). The jaws (42) and handles (44) are made of a stainless steel and are shaped to be biased apart at the end (46).
Corresponding slots (48) extend centrally along each jaw (42) from the free end (50) thereof, with the slots (48) each having a series of spaced apart arcuate notches (52) therein. The notches (52) are shaped to receive a sewing needle.
In use, the joined sides (16) of leaflets (12) are held against the side of the stent by between the jaws (42) whereafter they are stitched in position, the notches (52) acting as a template to ensure uniformity.
The tool is fairly simple to make but greatly facilitates manufacture of the stent as it permits both the valve member to be held in position and to be secured by a stitching whilst being so held. It will be appreciated that other embodiments of a tool exist which fall within the scope of the invention especially as regards the shape of the jaws and the slot therein.

Claims

CLAIMS:
1. A heart valve (1 ) which includes a valve member secured within a stent (2) with the valve member including a plurality of valve leaflets (12) secured together, the heart valve being characterised in that the leaflets are made of biological material having a maximum thickness of 0.3 mm.
2. ' A heart valve has claimed in claim 1 in which the biological material has a maximum thickness of 0.25 mm.
3. A heart valve has claimed in either one of claims 1 or 2 in which each leaflet has an arcuate shaped side (18) for attachment to the stent.
4. A heart valve has claimed in any one of the preceding claims in which the stent, in its crimped condition, has a maximum diameter of about 7.5 mm.
5. A heart valve has claimed in claim 4 in which the stent, in its crimped condition, has a maximum diameter of about 7.0 mm.
6. A heart valve has claimed in any one of the preceding claims in which the biological material is suitably treated kangaroo tissue
7. A heart valve as claimed in claim 6 in which the kangaroo tissue is a tissue treated using the ADAPT™ technology of Celxcel Pty Limited (BioMD Limited) of Perth, Western Australia.
8. A heart valve as claimed in any one of the preceding claims in which a sleeve (6) made of a porous, biocompatible material extends about the outer surface of the stent, at least partially along its length.
9. A heart valve has claimed in claim 8 in which the material of the sleeve is selected from porous polyester and expanded polytetraflouroethylene (PTFE).
10. A heart valve has claimed in either one of claims 8 or 9 in which the sleeve extends the full length of the stent.
11. A heart valve has claimed in any one of claims 8 to 10 in which sleeve is secured to the stent by stitching (22) typically extending along each end thereof.
12. A heart valve has claimed in any one of the preceding claims in which the stent is configured to initially expand at both ends (8, 9).
13. A heart valve has claimed in claim 12 in which the stent is in the form of a mesh defined by interconnected struts with the material of the stent being strengthened in a central region thereof by making the struts in that region stronger than the struts in the end regions.
PCT/IB2010/000398 2009-02-28 2010-02-26 A heart valve WO2010097694A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CN2010800097454A CN102395330A (en) 2009-02-28 2010-02-26 A heart valve
AU2010217291A AU2010217291B2 (en) 2009-02-28 2010-02-26 A heart valve
ZA2011/06839A ZA201106839B (en) 2009-02-28 2011-09-20 A heart valve

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ZA200809338 2009-02-28
ZA2008/09338 2009-02-28

Publications (1)

Publication Number Publication Date
WO2010097694A1 true WO2010097694A1 (en) 2010-09-02

Family

ID=42665051

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2010/000398 WO2010097694A1 (en) 2009-02-28 2010-02-26 A heart valve

Country Status (4)

Country Link
CN (1) CN102395330A (en)
AU (1) AU2010217291B2 (en)
WO (1) WO2010097694A1 (en)
ZA (1) ZA201106839B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220104302A (en) * 2013-03-15 2022-07-26 네비게이트 카디악 스트럭쳐스, 인크. Catheter-guided replacement valves apparatus and methods
CN104799975B (en) * 2015-04-20 2017-05-24 杭州嘉和众邦生物科技有限公司 Artificial bioprosthetic heart valve and production method thereof
CN110731836B (en) * 2018-07-20 2021-10-12 先健科技(深圳)有限公司 Heart valve

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489297A (en) * 1992-01-27 1996-02-06 Duran; Carlos M. G. Bioprosthetic heart valve with absorbable stent
US5562729A (en) * 1994-11-01 1996-10-08 Biocontrol Technology, Inc. Heart valve
US20030212454A1 (en) * 2002-05-08 2003-11-13 Scott Michael J. Compressed tissue for heart valve leaflets
US20040148018A1 (en) * 1999-01-26 2004-07-29 Carpentier Alain F. Flexible heart valve and associated connecting band
US20070239269A1 (en) * 2006-04-07 2007-10-11 Medtronic Vascular, Inc. Stented Valve Having Dull Struts
WO2009111241A2 (en) * 2008-02-29 2009-09-11 The Florida International University Board Of Trustees Catheter deliverable artificial multi-leaflet heart valve prosthesis and intravascular delivery system for a catheter deliverable heart valve prosthesis

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE8327414U1 (en) * 1983-09-23 1984-02-02 Reichart, Bruno, Prof. Dr. HEART VALVE PROSTHESIS
US7632738B2 (en) * 2003-06-24 2009-12-15 Sang-Yun Lee Wafer bonding method
US7542859B2 (en) * 2006-03-31 2009-06-02 Tokyo Electron Ltd. Creating a virtual profile library

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5489297A (en) * 1992-01-27 1996-02-06 Duran; Carlos M. G. Bioprosthetic heart valve with absorbable stent
US5562729A (en) * 1994-11-01 1996-10-08 Biocontrol Technology, Inc. Heart valve
US20040148018A1 (en) * 1999-01-26 2004-07-29 Carpentier Alain F. Flexible heart valve and associated connecting band
US20030212454A1 (en) * 2002-05-08 2003-11-13 Scott Michael J. Compressed tissue for heart valve leaflets
US20070239269A1 (en) * 2006-04-07 2007-10-11 Medtronic Vascular, Inc. Stented Valve Having Dull Struts
WO2009111241A2 (en) * 2008-02-29 2009-09-11 The Florida International University Board Of Trustees Catheter deliverable artificial multi-leaflet heart valve prosthesis and intravascular delivery system for a catheter deliverable heart valve prosthesis

Also Published As

Publication number Publication date
ZA201106839B (en) 2012-07-25
AU2010217291A1 (en) 2011-10-20
AU2010217291B2 (en) 2015-03-26
CN102395330A (en) 2012-03-28

Similar Documents

Publication Publication Date Title
US11241304B2 (en) Method for fluid flow through body passages
US10350096B2 (en) Expandable stent-graft system having diameter reducing connectors
US6576007B2 (en) Methods and apparatus for intraluminal placement of a bifurcated intraluminal graft
US10835367B2 (en) Devices for fluid flow through body passages
CN107106288A (en) Intracavitary overlay film frame is fixed
EP3949905A1 (en) Catheter assembly with valve crimping accessories
JP2017056262A (en) Stents and stent grafts
EP0680734A2 (en) Endovascular grafting apparatus, system and method and devices for use therewith
CN108836414A (en) Percutaneous leaflet increases
JPH0759802A (en) Multicapsule intraluminal implant device
JP2014527414A (en) Implantable and removable, customizable body conduit
US20220346937A1 (en) Multi-spiral self-expanding stent and methods of making and using the same
CN110313947A (en) Heart valve repair system
CN209153791U (en) Heart valve repair system
US11554034B2 (en) Method and assembly for securing an implantable medical device on a delivery system
US20230146457A1 (en) Devices and Methods for Securing Medical Devices within an Anatomy
AU2010217291B2 (en) A heart valve
JP2003190297A (en) Method and device for disposing forked in-vessel graft in vessel

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 201080009745.4

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 10745869

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 7216/DELNP/2011

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2010217291

Country of ref document: AU

ENP Entry into the national phase

Ref document number: 2010217291

Country of ref document: AU

Date of ref document: 20100226

Kind code of ref document: A

122 Ep: pct application non-entry in european phase

Ref document number: 10745869

Country of ref document: EP

Kind code of ref document: A1